Divi’s Lab shares in focus after Q4 PAT surges 26% YoY. Should you invest? – News Air Insight

Shares of Divi’s Laboratories are likely to remain in focus on Monday after the company reported a 26% YoY increase in its net profit at Rs 667 crore for the fourth quarter of FY25. The net profit for the year-ago period stood at Rs 531 crore.

The revenue from operations rose by 12.26% YoY to Rs 2,536 crore, up from Rs 2,259 crore reported in the same quarter of the last financial year.

Additionally, the board of directors of the company has also announced a dividend of Rs 30 per share for its shareholders, with July 25 fixed as the record date.

Sequentially, the company’s PAT increased by 12.28%, rising from Rs 594 crore in the third quarter of FY25. On the revenue front, the firm also recorded a 10.3% QoQ growth, with revenue climbing from Rs 2,297 crore.

Divi’s Laboratories reported a consolidated total income of Rs 2,671 crore for the quarter ended March 31, 2025, up from Rs 2,382 crore in the corresponding quarter last year.

After the Q4 results, here’s what brokerage firms have said:

Nuvama: Buy| Target price: Rs 7,225

Nuvama has revised its target price for Divi’s Laboratories to Rs 7,225 from the previous Rs 6,830, following a robust Q4FY25 performance characterised by impressive margin gains.

The brokerage highlighted the company’s strong showing, with expectations of double-digit growth driven by the next phase of expansion at Unit-III and the lucrative GLP-1 opportunity.

Additionally, Divi’s Q4FY25 performance included its best gross and EBITDA margins since Q2FY23/Q1FY23, propelled by growth in the API and nutraceuticals segments. Nuvama also emphasised the sustainability of Divi’s premium valuation amid new client and product additions.

Also read: Vodafone Idea shares in focus as govt rejects $5B dues waiver; telco moves SC citing ‘public interest’

Motilal Oswal: Neutral| Target price: Rs 6,540

Motilal Oswal has maintained a neutral rating on Divi’s Laboratories with a target price of Rs 6,540, citing limited upside at current valuation levels.

The brokerage noted that the company’s Q4FY25 results exceeded estimates, driven by a recovery in the generics segment.

It highlighted Divi’s bolstering of its CDMO capabilities in the peptide and contrast media space, positioning it to secure new contracts from innovator customers. Additionally, MOSL raised its earnings estimates for FY26/FY27 by 5% and 7%, respectively, factoring in increased investments from long-term contracts, moderating raw material costs, and improved execution in the generics segment.

MOSL projects a 25% earnings CAGR for Divi’s Laboratories over FY25- 27, emphasising that while the company is poised for growth, the current valuation presents limited room for further upside.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)